Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 19 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2017 Planned End Date changed from 1 Oct 2017 to 15 Jan 2018.